Objective: To assess the indications for and utility of diagnostic ultrasonography (US) in a series of consecutive patients with suspected traumatic peripheral nerve lesions (TPNL).
Methods: We retrospectively reviewed the electronic medical records of consecutive patients referred from February 2013 to May 2018 to our US laboratory. All included patients were examined using standard US equipment, with a 4-13MHz linear array transducer.
Results: In the analyzed period, we performed US examinations in 143 patients with 149 suspected TPNL. Electrodiagnostically (EDx) complete TPNL were found in 63 (45%), partial in 59 (42%), and only demyelination (i.e., neurapraxia) in four (3%) patients. TPNL could not be confirmed in 14 (10%) patients. Nerve discontinuity was not demonstrated by US in any of the patients with EDx incomplete nerve lesions. Contact of the nerve with osteosynthetic material (OSM) was found in eight of 33 patients (24%). In five patients, the nerve could not be adequately evaluated throughout its course due to extensive changes in the surrounding tissues.
Discussion: In acute situations, US is most useful in EDx complete TPNL to differentiate between nerve axonotmesis and neurotmesis. High-velocity trauma, lacerations, and bone fractures are all risk factors for neurotmesis. In chronic situations, US is useful in cases of functionally inefficient reinnervation, neuropathic pain, or progressive nerve dysfunction. In such patients, the surrounding tissues and the relation of the nerve to any OSM need to be carefully examined. US examination is probably not needed in patients with TPNL following acute blunt trauma, only minor clinical deficits and/or slightly/moderately abnormal EDx findings.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neucli.2020.01.007 | DOI Listing |
Clin Trials
January 2025
Rare Diseases Team, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Background/aims: Rare disease drug development faces unique challenges, such as genotypic and phenotypic heterogeneity within small patient populations and a lack of established outcome measures for conditions without previously successful drug development programs. These challenges complicate the process of selecting the appropriate trial endpoints and conducting clinical trials in rare diseases. In this descriptive study, we examined novel drug approvals for non-oncologic rare diseases by the U.
View Article and Find Full Text PDFIn the context of Chinese clinical texts, this paper aims to propose a deep learning algorithm based on Bidirectional Encoder Representation from Transformers (BERT) to identify privacy information and to verify the feasibility of our method for privacy protection in the Chinese clinical context. We collected and double-annotated 33,017 discharge summaries from 151 medical institutions on a municipal regional health information platform, developed a BERT-based Bidirectional Long Short-Term Memory Model (BiLSTM) and Conditional Random Field (CRF) model, and tested the performance of privacy identification on the dataset. To explore the performance of different substructures of the neural network, we created five additional baseline models and evaluated the impact of different models on performance.
View Article and Find Full Text PDFBiomark Med
January 2025
The Nutristasis Unit, Synnovis, St. Thomas' Hospital, London, UK.
This case describes a patient with pancreatic exocrine insufficiency and persistently elevated serum vitamin B12 concentrations that were not due to supplementation or associated with hepatic or hematological pathology. Laboratory investigations suggested the presence of macro-B12 as the cause of this patient's raised serum vitamin B12. Macro-B12 is often formed when vitamin B12-vitamin binding proteins (transcobalamin and haptocorrin) complex with immunoglobulins.
View Article and Find Full Text PDFClin Trials
January 2025
Department of Biostatistics, University of Florida, Gainesville, FL, USA.
Introduction: The sequential parallel comparison design has emerged as a valuable tool in clinical trials with high placebo response rates. To further enhance its efficiency and effectiveness, adaptive strategies, such as sample size adjustment and allocation ratio modification can be employed.
Methods: We compared the performance of Jennison and Turnbull's method and the Promising Zone approach for sample size adjustment in a two-phase sequential parallel comparison design study.
Ocul Immunol Inflamm
January 2025
Ocular Oncology Service, Institute of Oncology, Tecnologico de Monterrey, Monterrey, Mexico.
Purpose: To present the case of a young patient with BRAF V600E-mutant cutaneous melanoma who developed bilateral choroidal metastases complicated by neovascular glaucoma (NVG) in both eyes following the interruption of nivolumab therapy.
Methods: A 28-year-old female with primary cutaneous melanoma of the left hand underwent surgical resection and adjuvant nivolumab. Immunotherapy was discontinued due to immune-related acute interstitial nephritis.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!